Cargando…
First-line chemotherapy for ovarian cancer – the controversy continues
British Journal of Cancer (2002) 87, 813–814. doi:10.1038/sj.bjc.6600568 www.bjcancer.com © 2002 Cancer Research UK
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376182/ https://www.ncbi.nlm.nih.gov/pubmed/12373592 http://dx.doi.org/10.1038/sj.bjc.6600568 |
| _version_ | 1782154709327413248 |
|---|---|
| author | Kaye, S B |
| author_facet | Kaye, S B |
| author_sort | Kaye, S B |
| collection | PubMed |
| description | British Journal of Cancer (2002) 87, 813–814. doi:10.1038/sj.bjc.6600568 www.bjcancer.com © 2002 Cancer Research UK |
| format | Text |
| id | pubmed-2376182 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2002 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23761822009-09-10 First-line chemotherapy for ovarian cancer – the controversy continues Kaye, S B Br J Cancer Editorial British Journal of Cancer (2002) 87, 813–814. doi:10.1038/sj.bjc.6600568 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-10-07 2002-10-07 /pmc/articles/PMC2376182/ /pubmed/12373592 http://dx.doi.org/10.1038/sj.bjc.6600568 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Editorial Kaye, S B First-line chemotherapy for ovarian cancer – the controversy continues |
| title | First-line chemotherapy for ovarian cancer – the controversy continues |
| title_full | First-line chemotherapy for ovarian cancer – the controversy continues |
| title_fullStr | First-line chemotherapy for ovarian cancer – the controversy continues |
| title_full_unstemmed | First-line chemotherapy for ovarian cancer – the controversy continues |
| title_short | First-line chemotherapy for ovarian cancer – the controversy continues |
| title_sort | first-line chemotherapy for ovarian cancer – the controversy continues |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376182/ https://www.ncbi.nlm.nih.gov/pubmed/12373592 http://dx.doi.org/10.1038/sj.bjc.6600568 |
| work_keys_str_mv | AT kayesb firstlinechemotherapyforovariancancerthecontroversycontinues |